Search Results - "Navarro Compán, Victoria"

Refine Results
  1. 1

    Axial spondyloarthritis by Navarro-Compán, Victoria, Sepriano, Alexandre, El-Zorkany, Bassel, van der Heijde, Désirée

    Published in Annals of the rheumatic diseases (01-12-2021)
    “…Axial spondyloarthritis (axSpA) encompasses both radiographic and non-radiographic axSpA. It is a chronic inflammatory disease with a predilection for…”
    Get more information
    Journal Article
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6

    Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis by Navarro-Compán, Victoria, Deodhar, Atul, Bahiri, Rachid, Bushmakin, Andrew G, Cappelleri, Joseph C, Rammaoui, Jihane

    Published in Arthritis research & therapy (24-05-2024)
    “…Tofacitinib is an oral Janus kinase inhibitor for treatment of ankylosing spondylitis (AS). Time to improvement in core domains of AS was estimated in…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11

    A glance into the future of diagnosis and treatment of spondyloarthritis by Navarro-Compán, Victoria, Ermann, Joerg, Poddubnyy, Denis

    “…The last two decades have seen major developments in the field of spondyloarthritis (SpA), but there are still important unmet needs to address. In the future,…”
    Get full text
    Book Review Journal Article
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18

    Does gender influence outcome measures similarly in patients with spondyloarthritis? Results from the ASAS-perSpA study by Benavent, Diego, Capelusnik, Dafne, Ramiro, Sofia, Molto, Anna, López-Medina, Clementina, Dougados, Maxime, Navarro-Compán, Victoria

    Published in Rheumatic & musculoskeletal diseases open (01-09-2022)
    “…ObjectivesTo investigate the influence of gender on disease outcomes in patients with spondyloarthritis (SpA), including across SpA subtypes.MethodsData from…”
    Get full text
    Journal Article
  19. 19
  20. 20